SAINTE-FOY, QUEBEC--(Marketwire - May 13, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced it has extended its marketing presence in Asia through the execution of letters of intent with two major Korean generic drug companies for docetaxel active pharmaceutical ingredients. Each of these companies achieves sales of over US$1 billion on an annualized basis.
